Minerva Neurosciences Names Dr. Jay Saoud as Senior Vice President, Head of Research and Development
(Thomson Reuters ONE) -
WALTHAM, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.
(NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the
development of therapies to treat central nervous system (CNS) disorders, today
announced the appointment of Dr. Jay B. Saoud as senior vice president, head of
research and development. His responsibilities will focus on the clinical
development of the Company's portfolio of CNS products, including a Phase 3
trial with MIN-101 for schizophrenia, three Phase 2b trials with MIN-202 for
major depressive disorder (MDD) and insomnia disorder and a Phase 2b trial with
MIN-117 for MDD, all planned to begin in the second half of 2017, as well as the
completion of pre-clinical development and subsequent initiation of clinical
development with MIN-301 for Parkinson's disease.
Dr. Saoud brings to Minerva more than 25 years of research and development
experience in both industry and academia, where he played a critical role in the
design, conduct and reporting of clinical trials across multiple therapeutic
areas including CNS. He was previously president and chief executive officer of
PPRS Research, Inc., a strategic research and development consulting partner for
Minerva. Dr. Saoud formerly served as a compound development team leader and
head of exploratory development at Transform Pharmaceuticals (a Johnson &
Johnson company), U.S. head of statistical sciences for clinical pharmacology
and pharmacokinetics at Sanofi-Aventis and head of biometrics at ICOS
Corporation.
"Dr. Saoud's hands-on experience in clinical development and regulatory
activities will be invaluable as Minerva advances multiple product candidates
into later-stage and pivotal clinical trials beginning this year," said Dr. Remy
Luthringer, president and chief executive officer of Minerva. "His wide-ranging
skill set includes protocol development, clinical trial design and conduct,
global regulatory strategy, pre-clinical expertise, pharmacology,
pharmacokinetics and statistical sciences. Minerva has benefited significantly
from Dr. Saoud's contributions as a consultant during the past several years,
and we are delighted that he will now be working directly for the Company in a
leadership position."
Dr. Saoud has been involved in the development of more than 125 active molecules
in the central nervous system, diabetes, erectile dysfunction, hemorrhagic
fever, muscular dystrophy, and multiple sclerosis areas. He has a record of
successful pre-market and registration submissions in global regulatory
jurisdictions and approval of 11 New Drug Applications (NDAs), 10 of which have
resulted in sales in excess of $1 billion.
Dr. Saoud has published extensively in the areas of anxiety, depression, male
erectile dysfunction, muscular dystrophy, and sleep, including more than 300
articles and abstracts primarily in peer-reviewed journals. Prior to his
industry experience, he conducted clinical research at Columbia Presbyterian
Medical Center/New York State Psychiatric Institute and was chief of mental
health services within the New York City Department of Health's Correctional
Facilities. He received his undergraduate degree in pre-medicine and psychology
from the American University of Beirut, his master of science in Human
Development from the University of Oregon, and his doctoral training in
Experimental Cognition at City College of the City University of New York.
About Minerva Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company
focused on the development and commercialization of a portfolio of products to
treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in
clinical development for schizophrenia; MIN-202 (JNJ-42847922), in clinical
development for insomnia and major depressive disorder (MDD); MIN-117, in
clinical development for MDD; and MIN-301, in pre-clinical development for
Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global
Market under the symbol "NERV." For more information, please
visit www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995,
as amended. Forward-looking statements are statements that are not historical
facts, reflect management's expectations as of the date of this press release,
and involve certain risks and uncertainties. Forward-looking statements include
statements herein with respect to the timing and scope of future clinical trials
and results of clinical trials with MIN-101, MIN-202, MIN-117 and MIN-301. These
forward-looking statements are based on our current expectations and may differ
materially from actual results due to a variety of factors including, without
limitation, whether MIN-101, MIN-202, MIN-117 and MIN-301 will advance further
in the clinical trials process; management's ability to successfully achieve its
goals; our ability to raise additional capital to fund our operations on terms
acceptable to us; and general economic conditions. These and other potential
risks and uncertainties that could cause actual results to differ from the
results predicted are more fully detailed under the caption "Risk Factors" in
our filings with the Securities and Exchange Commission, including our Quarterly
Report on Form 10-Q for the quarter ended June 30, 2017, filed with
the Securities and Exchange Commission on August 3, 2017. Copies of reports
filed with the SEC are posted on our website at www.minervaneurosciences.com.
The forward-looking statements in this press release are based on information
available to us as of the date hereof, and we disclaim any obligation to update
any forward-looking statements, except as required by law.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via GlobeNewswire
![Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial](/modules/PresseInfo/thump/fp_fwd.gif "Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial")
Datum: 11.09.2017 - 14:30 Uhr
Sprache: Deutsch
News-ID 559435
Anzahl Zeichen: 6977
contact information:
Town:
Waltham
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 215 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Minerva Neurosciences Names Dr. Jay Saoud as Senior Vice President, Head of Research and Development"
steht unter der journalistisch-redaktionellen Verantwortung von
Minerva Neurosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
